Lonza Group Ltd
LO3A
Company Profile
Business description
Lonza Group is a contract development and manufacturing organization, or CDMO. It operates under four segments: small molecules, biologics, cell & gene, and capsules & health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing services throughout the entire lifecycle of a product from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.
Contact
Muenchensteinerstrasse 38
Basel4002
CHET: +41 613168111
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
18,686
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,462.60 | 40.90 | 0.49% |
| CAC 40 | 7,748.39 | 53.95 | 0.70% |
| DAX 40 | 23,509.54 | 156.85 | 0.67% |
| Dow JONES (US) | 41,368.45 | 254.48 | 0.62% |
| FTSE 100 | 8,564.78 | 33.17 | 0.39% |
| HKSE | 22,831.22 | 55.30 | 0.24% |
| NASDAQ | 17,928.14 | 189.98 | 1.07% |
| Nikkei 225 | 37,503.33 | 574.70 | 1.56% |
| NZX 50 Index | 12,605.07 | 138.04 | 1.11% |
| S&P 500 | 5,663.94 | 32.66 | 0.58% |
| S&P/ASX 200 | 8,231.20 | 39.50 | 0.48% |
| SSE Composite Index | 3,342.00 | 10.00 | -0.30% |